Inova Health Care Services Clinical Trials
Sponsors / Inova Health Care Services
62 ClinicalTrials.gov entries name Inova Health Care Services as the lead sponsor. The portfolio currently includes 18 recruiting studies, 3 active non-recruiting studies, and 24 completed studies. 11 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment, funding constraints. Cumulative planned enrollment across all listed trials is 16,032 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
62
Total Trials
18
Recruiting
3
Other Active
24
Completed
11
Terminated / Withdrawn
16,032
Total Enrollment
Termination reasons: Other45% · Recruitment36% · Funding9% · Regulatory9%
Recent Terminations
- Gestational Diabetes Mellitus, Class A2"Poor recruitment"
- Covid-19"FDA gave emergency use approval to COVID-19 convalescent plasma on 08/24/2020"
- Diabetes Mellitus, Type 2"Low enrollment"
- NCT03247972 Stopped Oct 2019Peripheral Arterial Disease"Research group transferred to another hospital"
- NCT03048019 Stopped Jun 2019Non-ST Elevation Myocardial Infarction (NSTEMI)"study terminated per PI"
- Breast Cancer"Terminated for lack of patient samples and funding"
- Chronic Obstructive Pulmonary Disease (COPD)"Unable to enroll"
- Colectomy"Lack of personnel available to complete study."
- Cardiac Perfusion
- Diabetes Mellitus"Blood sugar status of the enrolled subjects wasn't evaluable"
Active Trials (3 total)
- NCT05977686
- NCT06939751
- NCT06273683
- NCT06746428
- Cancer NANCT06931561
- NCT07335224
- Sickle Cell Disease PHASE2NCT06023199
- NCT06532890
- NCT05652218
- NCT06106360
- NCT06675448
- Acute Cardiac Syndrome PHASE4NCT07250763
- Analgesia NANCT07185425
- Sickle Cell Disease PHASE2NCT07023666
- Hepatocellular Carcinoma PHASE2NCT06789757
- Cirrhosis PHASE2/PHASE3NCT06007846
- NCT05433220
- NCT05422690
- Cesarean Delivery Affecting Newborn PHASE1/PHASE2NCT03298334
- NCT03378739